[{"address1": "42127 Pleasant Forest Court", "city": "Ashburn", "state": "VA", "zip": "20148-7349", "country": "United States", "phone": "703 980 4182", "website": "https://quoinpharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; a Master Service Agreement with Therapeutics Inc.; and a research agreement with Queensland University of Technology. The company was founded in 2018 and is based in Ashburn, Virginia.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael  Myers Ph.D.", "age": 61, "title": "Co-Founder, CEO & Chairman", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 661800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Denise  Carter", "age": 54, "title": "Co-Founder, COO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 537800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gordon Bruce Dunn J.D.", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 523385, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.0, "open": 1.03, "dayLow": 0.84, "dayHigh": 1.0301, "regularMarketPreviousClose": 1.0, "regularMarketOpen": 1.03, "regularMarketDayLow": 0.84, "regularMarketDayHigh": 1.0301, "beta": 2.123, "trailingPE": 0.6934783, "forwardPE": -2.6583333, "volume": 247028, "regularMarketVolume": 247028, "averageVolume": 603559, "averageVolume10days": 3582150, "averageDailyVolume10Day": 3582150, "bid": 1.16, "ask": 1.17, "bidSize": 800, "askSize": 4000, "marketCap": 1721135, "fiftyTwoWeekLow": 0.833, "fiftyTwoWeekHigh": 12.0, "fiftyDayAverage": 3.08954, "twoHundredDayAverage": 4.750065, "currency": "USD", "enterpriseValue": -6226358, "floatShares": 976410, "sharesOutstanding": 1798470, "sharesShort": 12984, "sharesShortPriorMonth": 2509, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.013200001, "heldPercentInsiders": 0.00526, "heldPercentInstitutions": 0.022939999, "shortRatio": 0.96, "shortPercentOfFloat": 0.0134000005, "bookValue": 5.737, "priceToBook": 0.16681193, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -8686573, "trailingEps": 1.38, "forwardEps": -0.36, "enterpriseToEbitda": 0.671, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "QNRX", "underlyingSymbol": "QNRX", "shortName": "Quoin Pharmaceuticals, Ltd.", "longName": "Quoin Pharmaceuticals, Ltd.", "firstTradeDateEpochUtc": 1470058200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "32cb2815-c927-3d74-8136-d444e5765139", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.957, "targetHighPrice": 240.0, "targetLowPrice": 3.4, "targetMeanPrice": 82.47, "targetMedianPrice": 4.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 10694861, "totalCashPerShare": 10.833, "ebitda": -9274461, "totalDebt": 3523733, "quickRatio": 2.986, "currentRatio": 3.151, "debtToEquity": 62.213, "returnOnAssets": -0.44027, "returnOnEquity": -1.32916, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-17"}]